Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular CarcinomaMin Yu, Zonghai Li, Ying Liu et al.|Molecular Therapy|2017Cited by 184
CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3/NF-κB/SDF-1α axis to enhance efficacy against pancreatic cancerRuixin Sun, Zonghai Li|Molecular Therapy|2023Cited by 80
Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1–CH3 fusion proteinZeyan Pan, Zonghai Li, Shengmeng Di et al.|Cancer Immunology Immunotherapy|2018Cited by 63
Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approachesMin Yu, Zonghai Li|Frontiers of Medicine|2017Cited by 52
Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinomaKesang Li, Zonghai Li|Oncotarget|2015Cited by 33